IRADIMED CORP Form 8-K Summary
Business Context and Reporting Period
This is a Current Report on Form 8-K filed by IRADIMED CORPORATION on May 17, 2019. The company is incorporated in Delaware and its common stock trades on the NASDAQ Capital Market under the symbol IRMD. The report addresses a specific corporate event regarding an executive trading plan.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statements or performance metrics.
Material Changes
There are no material changes to financial performance or operations reported in this filing. The sole material event is the establishment of a Rule 10b5-1 trading plan by an executive officer.
Management Commentary and Events
- Executive Trading Plan: On May 15, 2019, Brent Johnson, Executive Vice President of Worldwide Sales and Marketing, entered into a written stock trading plan (10b5-1 Plan).
- Plan Details: The plan allows Mr. Johnson to sell shares daily from May 2019 through November 2019, contingent on the market price reaching specified minimum thresholds.
- Disclosure: Transactions executed under this plan will be disclosed via Form 4 filings.
- Emerging Growth Company Status: The registrant is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Key Facts for Investor Verification
- Verify the specific price thresholds and share quantities in the 10b5-1 Plan via future Form 4 filings.
- Confirm the current trading status of IRMD on the NASDAQ Capital Market.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial performance.